Olivier Kosmider

This study integrates clinical and T-cell immune profiling to identify early biomarkers of response to CD3xBCMA bispecific antibody therapy in multiple myeloma.

This study investigates how UBA1 mutations in VEXAS syndrome lead to monocyte dysfunction and inflammation through RIPK1-mediated cell death and impaired NF-κB signaling.

This study investigates VEXAS anemia, showing that UBA1 mutations affect erythroblast differentiation but not mature red cells, leading to a mosaic erythroblastopenia.

This study identifies a pro-inflammatory role of Granzyme K-producing bystander CD8+ T cells in AML, which promote IL-8 secretion and may exacerbate disease progression.

This study characterizes a humanized in vivo bone marrow model, hOss, showing its impact on human hematopoietic development and clonal interactions.

The paper identifies ferritinophagy as a therapeutic target in quiescent leukemic stem cells, showing that inhibiting NCOA4 reduces leukemia.

This study uses single-cell multi-omics to map genotype-to-phenotype relationships in VEXAS syndrome, identifying PERK pathway activation as a therapeutic target.

This study identifies shared and distinct mechanisms of UBA1 inactivation in VEXAS syndrome and related diseases, revealing how different mutations affect ubiquitin transfer to E2 enzymes.

The paper uses single-cell data to show that hematopoietic differentiation involves a transient peak of gene expression variability, suggesting a stochastic process with a stage of cellular indetermination.

The paper examines TP53 allelic states in MDS patients, finding that bi-allelic targeting is linked to worse outcomes, while mono-allelic targeting does not differ from wild-type patients.